Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response.
Saved in:
| Title: | Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response. |
|---|---|
| Authors: | Kerth HA; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Kächele M; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Müller N; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Singh S; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Tulessin M; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany., Sacherl J; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Ates Öz E; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Su J; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Bester R; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Miko S; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Steiger K; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany., Mogler C; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany., Busch DH; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, Technical University of Munich, Munich, Germany., Wettengel JM; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Protzer U; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Kosinska AD; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Mar 12; Vol. 17, pp. 1771887. Date of Electronic Publication: 2026 Mar 12 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41909658 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kerth+HA%22">Kerth HA</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Kächele+M%22">Kächele M</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Müller+N%22">Müller N</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Singh+S%22">Singh S</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Tulessin+M%22">Tulessin M</searchLink>; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Sacherl+J%22">Sacherl J</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Ates+Öz+E%22">Ates Öz E</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Su+J%22">Su J</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Bester+R%22">Bester R</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Miko+S%22">Miko S</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Steiger+K%22">Steiger K</searchLink>; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Mogler+C%22">Mogler C</searchLink>; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Busch+DH%22">Busch DH</searchLink>; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Wettengel+JM%22">Wettengel JM</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Protzer+U%22">Protzer U</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Kosinska+AD%22">Kosinska AD</searchLink>; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 Mar 12; Vol. 17, pp. 1771887. <i>Date of Electronic Publication: </i>2026 Mar 12 (<i>Print Publication: </i>2026). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41909658 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fimmu.2026.1771887 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1771887 Titles: – TitleFull: Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kerth HA – PersonEntity: Name: NameFull: Kächele M – PersonEntity: Name: NameFull: Müller N – PersonEntity: Name: NameFull: Singh S – PersonEntity: Name: NameFull: Tulessin M – PersonEntity: Name: NameFull: Sacherl J – PersonEntity: Name: NameFull: Ates Öz E – PersonEntity: Name: NameFull: Su J – PersonEntity: Name: NameFull: Bester R – PersonEntity: Name: NameFull: Miko S – PersonEntity: Name: NameFull: Steiger K – PersonEntity: Name: NameFull: Mogler C – PersonEntity: Name: NameFull: Busch DH – PersonEntity: Name: NameFull: Wettengel JM – PersonEntity: Name: NameFull: Protzer U – PersonEntity: Name: NameFull: Kosinska AD IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 03 Text: 2026 Mar 12 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1664-3224 Numbering: – Type: volume Value: 17 Titles: – TitleFull: Frontiers in immunology Type: main |
| ResultId | 1 |
